A review on vasohibin and ocular neovascularization
| Autor: | Xiao-Nan Hu, Yan Ni, Yu-Zhi Ding, Jie Luan |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
ocular neovascularization
Oncology medicine.medical_specialty genetic structures business.industry Angiogenesis vasohibin Life quality Ocular neovascularization Retinal Disease Review Article Ocular angiogenesis eye diseases retinal neovascularization Vascular endothelial growth factor Ophthalmology chemistry.chemical_compound lcsh:Ophthalmology chemistry lcsh:RE1-994 Internal medicine Medicine business Adverse effect |
| Zdroj: | Int J Ophthalmol International Journal of Ophthalmology, Vol 13, Iss 6, Pp 1004-1008 (2020) |
| ISSN: | 2222-3959 |
| Popis: | Ischemic and neovascular disease is one of the most difficult ocular diseases to deal with nowadays. Redundancy, poor visual acuity and decreased life quality are bothering patients and ophthalmologists for decades. After vascular endothelial growth factor (VEGF) was found to be a primary factor in promoting retinal angiogenesis, intravitreal injection of anti-VEGF drugs has been the first-line treatment. Whereas, some patients are refractory to this therapy and problems of economic burden, local complications and adverse effects promote researches into other possible targets. The vasohibin (VASH) family is a newly-investigated factor in modulating ocular angiogenesis. The family includes VASH1 and VASH2, which show opposite effects of inhibiting and accelerating angiogenesis respectively. Positive results have been reported in cellular and animal experiments. With further researches, it can be a promising future target of treating ocular neovascular diseases. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|